Central Oncology Review
Specialized Institutional Review Board (IRB) Services for an Evolving Regulatory Landscape
Aligned with the needs of the growing and increasingly complex field of oncology, Advarra’s Central Oncology Review (COR) provides the robust human subject protections review cancer research institutions expect.
Learn More About COR
-
Expertise
The COR IRB roster includes distinguished oncologists and individuals from leading cancer centers, including ASCO-member oncologists and patient advocates. COR is experienced in reviewing specialized research protocols such as basket, umbrella, and targeted therapy trials.
-
Accelerated Startup
Advarra IRB members understand the latest oncology methodologies and discoveries, which prevents unnecessary follow-up during the review process. COR helps researchers meet study activation milestones more quickly and speed patient accrual.
-
Collaboration
COR acts as an extension of internal research programs, providing expertise and support to help institutions navigate the latest developments in oncology research, gene therapy review, and single IRB (sIRB) mandates. Our IRB has supported 100% of all NCI-designated cancer centers conducting clinical trials.
-
Transparency
COR maintains a transparent review process, offering access to documents and data in real time with the added ability to discuss issues with a dedicated support specialist. Always know the study’s review status, anytime, anywhere.
IRB Experience in Oncology
- Antibody-drug conjugates
- Bladder/urinary tract cancer
- Blood and lymph cancers
- Breast cancer
- Cancer diagnostics
- Cervical cancer
- Chemotherapy
- Colon/colorectal cancer
- Endometrial cancer
- Gastric cancer
- Gene therapy
- Head and neck cancer
- Immunotherapy (such as CAR-T cell therapy)
- Liver cancer
- Lung cancer
- Ovarian cancer
- Pancreatic cancer
- Palliative care management
- Precision medicine (such as basket, umbrella, and targeted therapy trials)
- Prostate cancer
- Radiotherapy
- Renal cancer
- Sarcoma
- Skin cancer
Developed and Led By Key Experts in Oncology Research and Institutional Human Subject Protection Programs
Michele Russell-Einhorn, JD
Chief Compliance Officer and Institutional Official, Advarra
Judith Carrithers, JD, MPA
VP, IRB Review, Advarra
Planning for Gene Therapy Research? Plan for IBC Review
Advarra’s coordinated IRB and IBC reviews help streamline the startup process
COR FAQs
Can Advarra serve as the single IRB for federally funded research?
Yes, Advarra oversees many single site and multisite studies supported by the NIH, NCI, DoD, and other agencies.
Can Advarra serve as the single IRB for oncology network research?
Yes, Advarra has experience supporting therapeutically specialized research networks. For more information, see IRB Services for Institutions, Health Systems, and Research Consortia.
How do I defer IRB oversight to Advarra?
We’ll work with your organization to establish a deferral agreement. Then we will coordinate with institutional leadership to accommodate local requirements and train teams as needed. Contact our team to get started.
Streamline your research operations with OnCore, the preferred enterprise research CTMS of NCI-designated cancer centers
Related Resources
Legislation to Advance Equality and Inclusion in Oncology Clinical Trials
The Clinical Treatment Act and Henrietta Lacks Enhancing Cancer Research Act aims to increase diversity in oncology clinical trials
Q&A – The New Urgency of Clinical Trials: How Oncology Leads the Evolution
How has the COVID-19 pandemic changed oncology research--and research in general? Read more for the follow-up blog to our recent symposium:
How Oncology Research Is Advancing Better Research
Innovations in oncology have sparked advancements in the clinical trial industry and empowered COVID-19 research. Read more:
